Johnson & Johnson JNJ
News
Sarepta Therapeutics Set to Join S&P MidCap 400
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Johnson & Johnson On Track for Largest Percent Decrease Since August 2023 — Data Talk
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation
J&J-Linked Rapport Therapeutics Files For IPO
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
J&J scores lowest spread of year on bonds to help fund $13 billion bid for Shockwave
J&J to Sell Remaining Stake in Kenvue Spinoff
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Shockwave Medical Reports First Quarter 2024 Financial Results
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV)
Johnson & Johnson unveils latest plan to settle ovarian cancer talc claims
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset